Avenue Therapeutics (ATXI) Q3 2026 earnings summary

Executive summary

• Product candidates are ATX-04 for Pompe disease and IV tramadol for post-operative pain; no products are currently for sale, and operating losses are expected to continue.

• Q3 net loss was $691,000; 9M net loss was $2.076 million versus $2.221 million in 2025, while 9M 2026 revenue was zero.

Financial highlights

• Q3 operating expenses were $704,000 versus $724,000 YoY; R&D rose to $212,000 from $177,000, while G&A declined to $492,000 from $547,000.

• 9M operating expenses fell to $2.125 million from $3.735 million; the prior-year period included $1.404 million of AnnJi termination and transfer revenue.

• Cash and equivalents were $1.520 million at September 30, 2026, versus $2.855 million at December 31, 2025; accumulated deficit was $107.6 million.

Outlook and guidance

• R&D costs are expected to increase as ATX-04 development advances and regulatory work continues; operating losses are expected for at least the next several years.

• FDA discussions are underway on a pivotal Pompe study design; after those discussions, funding is to be sought to finance and initiate the trial.

• IV tramadol's next study depends on obtaining financing or a partnership; the development path is being evaluated.